

R E V I E W

Muscle stem cells: what's new in orthopedics?

Carlo Biz¹, Alberto Crimi¹, Ilaria Fantoni¹, Assunta Pozzuoli^{1,2}, Pietro Ruggieri¹

¹ Orthopedic Clinic, Department of Surgery, Oncology and Gastroenterology DiSCOG, University of Padova, Padova, Italy;

² Musculoskeletal Pathology and Oncology Laboratory, Department of Orthopedics and Orthopedic Oncology, University of Padova, Padova, Italy

Summary. *Background and aim of the work:* Adult stem cells were studied as a source of potentially useful development for tissue engineering and repair techniques. The aim of this review is to clarify the actual and possible uses of muscle stem cells in orthopedics. *Methods:* A selection of studies was made to obtain a homogeneous and up to date overview on the muscle stem cells applications. *Results:* In recent years muscle was studied as a good source of adult stem cells that can differentiate into different cell lineages. Muscle stem cells are a heterogeneous population of cells, which demonstrated in vitro a great potential for the regeneration and repair of muscle, bone and cartilage tissue. Among muscle stem cells, satellite stem cells are the most known progenitor cells: they can differentiate in osteoblasts, adipocytes, chondrocytes and myocytes. *Conclusions:* Although muscle stem cells are a promising field of research, more pre-clinical studies in animal models are still needed to determine the safety and efficiency of the transplant procedures in humans. (www.actabiomedica.it)

Key words: muscle stem cells, satellite cells, muscle repair, bone healing, cartilage healing

Introduction

Stem cells can be adult stem cells or embryonic stem cells. They can be totipotent (cells capable of becoming an entire organism), pluripotent (cells capable of generating the three germ layers) and multipotent (cells of a specific germ layer becoming organ-specific progenitors). The adult stem cells have two characteristics: self-renewal and multi-lineage differentiation (1). Stem cells give tissues and organs the possibility to develop and regenerate. Biochemical and bio-mechanical signals regulate proliferation and differentiation of stem cells, typical of early development and tissue regeneration (2). There is considerable heterogeneity in the classification of Muscle Stem Cells (MSCs). The International Society of Cell and Gene Therapy (ISCT) system is still the current classifying system for MSCs (3). After birth, muscle regeneration is mediated mostly by Satellite Cells (SCs): these cells are flattened cells, located between the sarcolemma and the basal lamina

of myofibers (4). They represent a heterogeneous population of self-renewable stem cells. They are quiescent in vivo, but they can be activated by increased muscle work such as after-load-induced hypertrophy, prolonged exercise, and in some pathological conditions such as myotraumas. When activated, SCs proliferate, migrate from the myofibers, and express specific myogenic markers, thus becoming muscle precursor cells (MPCs). Recent studies on Muscle Stem Cells (MSC) highlighted their possible use in repair of muscles and regeneration of tissues like bone and cartilage. MSCs can be separated in 2 subtypes CD45+ and CD45-. The first ones, if isolated by the muscle, have a limited myogenic potential but a high hematopoietic potential. The CD45- cells have a high myogenic potential and a low hematopoietic potential (5-7). Environmental signals like Wingless/Integrated 8 (Wnt8) can modify the differentiation potential of the MSCs (8).

MSCs demonstrated good transplantation behavior in animal models and resistance to in vitro manipu-

lation, becoming in this way very useful in the repair and regeneration of musculoskeletal tissues (9).

The aim of this review is to investigate the actual and possible use of muscle stem cells in musculoskeletal diseases.

MSCs and factors that regulate stem cell self-renewal and differentiation

MSCs are related with endothelial cells of the capillaries or with pericytes; some myogenic-endothelial progenitor cells are in fact CD34+ and CD45- (10). These cells can differentiate in vascular endothelial cells or musculoskeletal cells (11). Some studies demonstrated that MSCs are associated with vascular structures, particularly with the myofibers surrounding capillaries (6, 12). The hypothesis is that repair of the local skeletal muscle is made by resident stem cells (8). MDSCs cell cycle is modified and enhanced in vitro by growth factors: insulin-like growth factor-1 (IGF-1), epithelial growth factor (EGF), stem cell factor (SCF) and fibroblast growth factor-2 (FGF-2) (13).

Harvesting technique

One of the major limitations in the use of satellite cells is the low number of extracted cells due to the small size of biopsies and the difficult separation from other cellular components, it is still a challenge to obtain enough muscle stem cells in vitro. The first effort to obtain a method for dissociating mammalian muscle into intact, living single fibers was introduced by Bekoff and Betz in 1977 (14). Afterwards, Bischoff modified the Bekoff and Betz method to permit the study of SC proliferation on rat flexor digitorum brevis muscle fibers in vitro (15). Rosenblatt et al. (16) proposed a method for isolating myogenic cells based on the previous method described by Bischoff (15). This allows isolation of SCs from single muscle fibers. Cells can easily be removed from culture and analyzed. In this way, differences in myogenic cell behavior can be detected with greater sensitivity and reliability, both within and between muscles (16). Muscle stem cells can be obtained with two different approaches: single fiber isolation and whole muscle enzymatic digestion. There are different protocols to obtain these cells. An

efficient protocol to isolate and expand in culture human muscle precursor cells from different skeletal muscles was described by Franzin et al. (17).

Muscle regeneration and repair

Muscle injuries usually imply a mechanism of shearing, with torn connective tissue and myofibers, or a punctiform damage. In this case only the myofibers are damaged while connective tissue does not present damage. Immediately after the trauma there is hematoma formation, muscle degeneration, necrosis and infiltration of inflammatory cells (18). After this phase there is a reparative phase, with phagocytosis of necrotic or damaged tissue, muscle fiber regeneration, formation of scar tissue and neovascularization (19). In the following remodeling phase there is muscle regeneration and reorganization of scar tissue. The MDSCs (CD45+) are involved in muscle regeneration (7). MDSCs can differentiate in myofibroblast-like cells in vitro and so can contribute to scar formation after muscle injury in vivo, mainly if stimulated with Tumor Growth Factor β -1 (TGF- β 1) (20, 21). The activation of SCs induces fibroblasts to produce extracellular matrix and proliferate (22). This extracellular matrix production in some traumas can lead to excessive scar formation with insufficient muscle regeneration (21). In these cases, some studies demonstrated that some signals can prevent formation of an over-fibrotic scar (gamma interferon, decorin) and others (IGF-1) can improve muscle healing (23-25). In any case, MSC transplantation techniques still have bad results (26). Recent studies highlighted that only a small part of the satellite cells are true muscle stem cells. This sub-population proliferates slower than the main one (27, 28), but it is in charge of the long-term survival of implanted cells (29). Rossi et al. demonstrated how hydrogel technology can be applied to skeletal muscle for the reconstruction of damaged muscles, designing the delivery of either stem cells or muscle progenitor cells (30).

Bone healing

Fracture repair involves: acute response to damage, intra-membraneous bone formation, endochon-

dral bone formation, cartilage formation and bone remodeling (18). Different techniques were studied to repair bone defects, in particular biologically enhanced allografts, gene- or cell-based tissue engineering (31, 32). MSCs can be induced to have osteogenic differentiation and can heal bone defects in animals (18). A subpopulation of MSCs in skeletal muscle can be induced by osteogenic proteins. It was shown that murine MDSCs genetically modified to express bone morphogenetic protein- 2 (BMP-2) and BMP-4, a group of proteins of the TGF family with a pivotal role in bone remodeling, can differentiate into an osteogenic lineage, determining, in these studies, bone healing in long bones in mice models (33-38). Moreover, vascular endothelial growth factor (VEGF) modulates bone formation, improving bone healing after implantation of MDSCs with expression of BMP2 and BMP4 in animal models (39, 40). There are ongoing Clinical Trials on humans.

Articular cartilage repair

Cartilage is known to have poor healing capacity. Adult articular cartilage has no vascularization or innervation, and defects with a diameter larger than 2-4 mm usually do not heal (41, 42). Nowadays, the main operative treatments of articular cartilage defects are: total joint replacement, transplantation and articular surface debridement. The tissue repaired with transplantation does not integrate and degenerate over time (43).

Cartilage repair via chondrocyte transplantation

There are different articular cartilage repair techniques, all of them with unproven long-term efficacy in animal models (44, 45). Investigated procedures are: transplantation of cartilage plugs (46), autologous chondrocytes transplantation (44), allogenic chondrocytes transplantation (47) and fetal chondrocytes transplantation (48, 49).

Muscle-derived cells for cartilage repair

A satisfactory result was obtained in cartilage healing using muscle-derived stem cells. MSCs showed

if transplanted in cartilage articular defects artificially created in rabbits a result comparable to chondrocytes transplantation (50), with the production of type-II collagen (51).

Other future promising techniques for cartilage repair

Furthermore, genetic engineering can have an important role in regenerative medicine. An adenoviral vector (with IGF-1 expression) was used to transduce and enhance equine mesenchymal stem cells (53). Cells so enhanced secreted IGF-1 stimulating changes in cartilage matrix gene expression (54), inducing cartilage healing. Other growth factors can stimulate stem cells proliferation, migration and differentiation: BMPs bone morphogenetic proteins (BMP), Transforming growth factor (TGF)-beta1, beta2 and beta3 and fibroblast growth factors (54). A better understanding of these factors could lead to a combined use of stem cells and growth factor in articular defects.

Conclusions

There are still many obstacles in the use of MSCs in regenerative medicine. Their transplantation as clinical therapy is far from being efficient (55). Some clinical studies reported the use of MSCs to treat pathologies like rotator cuff tears (56) and articular cartilage damage (57). Other fields of application were clinical trials on human cardiac disease, stress incontinence of the bladder and muscular dystrophies (58). The biological properties and effects of MSCs in vivo on musculoskeletal tissue healing remains overall not satisfactory. An obstacle to the success of myogenic stem cell therapy in humans is to obtain a sufficient number of freshly isolated satellite cells (59). Basic science studies and preclinical works are needed before the use in clinical practice in orthopedics of these techniques with an acceptable level of efficiency and safety. Recent research is focused on the clinical use of reconstructive techniques to obtain repair of tissue loss in murine models (60). The increasing knowledge of molecular mechanisms at the basis of the activation, differentiation, and phenotypic switch of the MSCs is the first step towards the comprehension of their role in muscular pathologies. The promising combination of adult

stem cell use, gene therapy techniques and tissue engineering will obtain new and effective therapies for the healing of tissues with low regenerative capacity.

Authors' contribution:

C.B. and A.C.: study concept and design; drafting of the paper;

A.C. and I.F.: literature research and data collection;

C.B. and A.P.: analysis and interpretation of data;

P.R.: final approval of the version to be published.

References

- Bentzinger CF, Wang YX, Rudnicki MA. Building muscle: molecular regulation of myogenesis. *Cold Spring Harb Perspect Biol* 2012 Feb 1;4(2).
- Blaauw B., Schiaffino S., Reggiani C. Mechanisms modulating skeletal muscle phenotype. *Compr Physiol* 2013 Oct;3(4):1645-87.
- Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy* 2005;7(5):393-395.
- Collins CA, Olsen I, Zammit PS, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle stem cell niche. *Cell* 2005 Jul 29;122(2):289-301.
- McKinney-Freeman SL, Jackson KA, Camargo FD, Ferrari G, Mavilio F, Goodell MA. Muscle-derived hematopoietic stem cells are hematopoietic in origin. *Proc Natl Acad Sci USA* 2002;99(3):1341-1346.
- Qu-Petersen Z, Deasy B, Jankowski R, et al. Identification of a novel 21 population of muscle stem cells in mice: potential for muscle regeneration. *J Cell Biol* 2002;157(5):851-864.
- Cao B, Zheng B, Jankowski RJ, et al. Muscle stem cells differentiate into haematopoietic lineages but retain myogenic potential. *Nat Cell Biol* 2003;5(7):640-646.
- Poleskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. *Cell* 2003;113(7):841-852.
- Urbani L, Piccoli M, Franzin C, Pozzobon M, De Coppi P. Hypoxia increases mouse satellite cell clone proliferation maintaining both in vitro and in vivo heterogeneity and myogenic potential. *PLoS One* 2012;7(11).
- Brighton CT, Lorich DG, Kupcha R, Reilly TM, Jones AR, Woodbury RA II. The pericyte as a possible osteoblast progenitor cell. *Clin Orthop* 1992;(275):287-299.
- Tamaki T, Akatsuka A, Ando K, et al. Identification of myogenic-endothelial progenitor cells in the interstitial spaces of skeletal muscle. *J Cell Biol* 2002;157(4):571-577.
- Lee JY, Qu-Petersen Z, Cao B, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. *J Cell Biol* 2000;150(5):1085-1100.
- Deasy BM, Qu-Petersen Z, Greenberger JS, Huard J. Mechanisms of muscle stem cell expansion with cytokines. *Stem Cells* 2002;20(1):50-60.
- Bekoff, A., Betz. W. J. Properties of isolated adult rat muscle fibres maintained in tissue culture. *J Physiol* 1977 Oct;271(2):537-47.
- Bischoff, R. Proliferation of muscle satellite cells on intact myofibers in culture. *Dev Biol* 1986 May;115(1):129-39.
- Rosenblatt J, Lunt AI, Parry DJ, Partridge T.A. Culturing satellite cells from living single muscle fiber explants. *In Vitro Cell Dev Biol Anim* 1995 Nov;31(10):773-9.
- Franzin, C, Piccoli M, Urbani L, Biz C, Gamba P, De Coppi P, Pozzobon M. Isolation and expansion of muscle precursor cells from human skeletal muscle biopsies. *Stem Cell Heterogeneity. Methods Mol Biol* 2016;1516:195-204.
- Peng H, Huard J. Muscle-derived stem cells for musculoskeletal tissue regeneration and repair. *Transpl Immunol* 2004 Apr;12(3-4):311-9.
- Peng H, Huard J. Stem cells in the treatment of muscle and connective tissue diseases. *Curr Opin Pharmacol* 2003 Jun;3(3):329-33.
- Li Y, Foster W, Deasy BM, et al. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. *Am J Pathol* 2004 Mar;164(3):1007-19.
- Li Y, Huard J: Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. *Am J Pathol* 2004 Mar;164(3):1007-19.
- Hurme T, Kalimo H, Sandberg M, Lehto M, Vuorio E. Localization of type I and III collagen and fibronectin production in injured gastrocnemius muscle. *Lab Invest* 1991;64(1):76-84.
- Sato K, Li Y, Foster W, et al. Improvement of muscle healing through enhancement of muscle regeneration and prevention of fibrosis. *Muscle Nerve* 2003;28(3):365-372.
- Foster W, Li Y, Usas A, Somogyi G, Huard J. Gamma interferon as an antifibrosis agent in skeletal muscle. *J Orthop Res* 2003;21(5):798-804.
- Beauchamp JR, Morgan JE, Pagel CN, Partridge TA. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. *J Cell Biol* 1999;144(6):1113-1122.
- Schultz E. Satellite cell proliferative compartments in growing skeletal muscles. *Dev Biol* 1996;175(1):84-94.
- Smith J, Schofield PN. Stable integration of a mdx skeletal muscle cell line into dystrophic (mdx) skeletal muscle; evidence for stem cell status. *Cell Growth Differ* 1997;8(8):927-934
- Rossi CA, Flaibani M, Blaauw B, et al. In vivo tissue engineering of functional skeletal muscle by freshly isolated satellite cells embedded in a photopolymerizable hydrogel. *FASEB J* 2011 Jul;25(7):2296-304.
- Awad HA, Zhang X, Reynolds DG, Guldberg RE, O'Keefe

- RJ, Schwarz EM. Recent advances in gene delivery for structural bone allografts. *Tissue Eng* 2007 Aug;13(8):1973-85.
30. Zhang X, Awad HA, O'Keefe RJ, Gulberg RE, Schwarz EM. A perspective: Engineering periosteum for structural bone graft healing. *Clin Orthop Relat Res* 466:1777-1787, 2008
 31. Lee JY, Musgrave D, Pelinkovic D, et al. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. *J Bone Joint Surg Am.* 2001 Jul;83-A(7):1032-9.
 32. Lee JY, Qu-Petersen Z, Cao B, et al. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. *J Cell Biol.* 2000 Sep 4;150(5):1085-100.
 33. Shen HC, Peng H, Usas A, et al. Ex vivo gene therapy-induced endochondral bone formation: Comparison of muscle-derived stem cells and different subpopulations of primary muscle-derived cells. *Bone* 2004 Jun;34(6):982-92.
 34. Shen HC, Peng H, Usas A, Gearhart B, Fu FH, Huard J. Structural and functional healing of critical-size segmental bone defects by transduced muscle-derived cells expressing BMP4. *J Gene Med* 2004 Sep;6(9):984-91.
 35. Peng H, Usas A, Gearhart B, Young B, Olshanski A, Huard J. Development of a self-inactivating tet-on retroviral vector expressing bone morphogenetic protein 4 to achieve regulated bone formation. *Mol Ther.* 2004 Jun;9(6):885-94.
 36. Wright V, Peng H, Usas A, Gearhart B, Cummins J, Huard. BMP4-expressing muscle-derived stem cells differentiate into osteogenic lineage and improve bone healing in immunocompetent mice. *Mol Ther* 2002;6(2):169-178.
 37. Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. *J Clin Invest* 2002;110(6):751-759.
 38. Mori S, Yoshikawa H, Hashimoto J, et al. Antiangiogenic agent (TNP-470) inhibition of ectopic bone formation induced by bone morphogenetic protein-2. *Bone* 1998;22(2):99-105.
 39. O'Driscoll SW: The healing and regeneration of articular cartilage. *J Bone Joint Surg Am* 1998 Dec;80(12):1795-812.
 40. Koval KJ: Orthopaedic Update 7. American Academy of Orthopaedic Surgeons, Dallas, TX, 2002
 41. O'Driscoll SW, Keeley FW, Salter RB. Durability of regenerated articular cartilage produced by free autogenous periosteal grafts in major full-thickness defects in joint surfaces under the influence of continuous passive motion. A follow up report at 1 year. *J Bone Joint Surg* 1988;70(4):590-606
 42. Breinan HA, Minas T, Hsu HP, Nehler S, Sledge CB, Spector M. Effect of cultured autologous chondrocytes on repair of chondral defects in a canine model. *J Bone Joint Surg Am* 1997;79(10):1439-1451.
 43. Sams AE, Nixon AJ. Chondrocyte-laden collagen scaffolds for resurfacing extensive articular cartilage defects. *Osteoarthritis Cartilage* 1995;3(1):47-59.
 44. Hangody L, Kish G, Kárpáti Z, Udvarhelyi I, Szigeti I, Béli M. Mosaicplasty for the treatment of articular cartilage defects: application in clinical practice. *Orthopedics* 1998;21(7):751-756.
 45. Wakitani S, Kimura T, Hirooka A, et al. Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. *J Bone Joint Surg (Br)* 1989;71(1):74-80.
 46. Itay S, Abramovici A, Nevo Z. Use of cultured embryonal chick epiphyseal chondrocytes as grafts for defects in chick articular cartilage. *Clin Orthop* 1987;(220):284-301.
 47. Robinson D, Halperin N, Nevo Z. Regenerating hyaline cartilage in articular defects of old chickens using implants of embryonal chick chondrocytes embedded in a new natural delivery substance. *Calcified Tissue Int* 1990;46(4):246-253.
 48. Worster AA, Brower-Toland BD, Fortier LA, Bent SJ, Williams J, Nixon AJ. Chondrocytic differentiation of mesenchymal stem cells sequentially exposed to transforming growth factor-beta1 in monolayer and insulin-like growth factor-I in a three-dimensional matrix. *J Orthop Res* 2001;19(4):738-749.
 49. Adachi N, Sato K, Usas A, et al. Muscle derived cell based ex vivo gene therapy for treatment of full thickness articular cartilage defects. *J Rheumatol* 2002;29(9):1920-1930.
 50. Nixon AJ, Brower-Toland BD, Bent SJ, et al. Insulinlike growth factor-I gene therapy applications for cartilage repair. *Clin Orthop Relat Res.* 2000 Oct;(379 Suppl):S201-13.
 51. Brower-Toland BD, Saxer RA, Goodrich LR, et al. Direct adenovirus-mediated insulin-like growth factor I gene transfer enhances transplant chondrocyte function. *Hum Gene Ther* 2001;12(2):117-129.
 52. O'Connor WJ, Botti T, Khan SN, Lane JM.: The use of growth factors in cartilage repair. *Orthop Clin North Am* 31:399-410, 2000
 53. Dumont NA, Bentzinger CF, Sincennes MC, Rudnicki MA. Satellite cells and skeletal muscle regeneration. *Compr Physiol* 2015 Jul 1;5(3):1027-59.
 54. Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR, Pellanda R. Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. *Knee Surg Sports Traumatol Arthrosc* 2012; 20(2):373-377.
 55. Hernigou P, Flouzat Lachaniette CH, Delambre J, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. *Int Orthop* 2014;38(9):1811-1818
 56. Kim YS, Lee HJ, Choi YJ, Kim YI, Koh YG. Does an injection of a stromal vascular fraction containing adipose-derived mesenchymal stem cells influence the outcomes of marrow stimulation in osteochondral lesions of the talus? A clinical and magnetic resonance imaging study. *Am J Sports Med.* 2014;42(10):2424-2434.
 57. Kim YS, Park EH, Kim YC, Koh YG. Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochondral lesions of the talus. *Am J Sports Med* 2013;41(5): 1090-109
 58. MacLean, S, Khan WS, Malik AA, Anand S, Snow M. The

- potential of stem cells in the treatment of skeletal muscle injury and disease. *Stem Cells Int* 2012;2012:282348.
59. Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cos-su G. Repairing skeletal muscle: Regenerative potential of skeletal muscle stem cells. *J Clin Invest* 2010 Jan;120(1):11-9.
60. Wang HD, Lough DM, Kurlander DE, Lopez J, Quan A, Kumar AR. Muscle-Derived Stem Cell Enriched Scaffolds Are Capable Of Enhanced Healing Of A Murine Volumetric Muscle Loss Defect. *Plast Reconstr Surg*. 2018 Nov 26.

Received: 26 October 2018

Accepted: 10 December 2018

Correspondence:

Carlo Biz MD, Assistant Professor,

Orthopaedic Clinic, Department of Surgery,

Oncology and Gastroenterology DiSCOG,

University of Padua, via Giustiniani 2 - 35128 Padova, Italy

Tel. 0039 049 8213239

E-mail: carlo.biz@unipd.it